Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain. (Q42817278)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Evaluation of analgesic, antioxidant, cytotoxic and metabolic effects of pregabalin for the use in neuropathic pain (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Monika Głuch-Lutwin

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

Tadeusz Librowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Barbara Nawiesniak

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

published in

Neurological Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

948-958

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23816319%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

The evidence for pharmacological treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin for painful neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

CLINICAL REVIEW: Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Diabetic painful neuropathy: current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

What is new in neuropathic pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin, S-(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Mechanisms and treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Evidence-based interventional pain medicine according to clinical diagnoses. 18. Painful diabetic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Painful diabetic neuropathy: treatment and future aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Treatment of diabetic sensory polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

New treatment options in the management of fibromyalgia: role of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin: an antiepileptic agent useful for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

The impact of background antiepileptic drugs on the efficacy and safety of pregabalin in treating partial-onset seizures: a post hoc analysis of combined clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin in acute and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Safety and efficacy of pregabalin in patients with central post-stroke pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Combination therapy for neuropathic pain: a review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy of pregabalin in neuropathic pain in paediatric oncological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin for the treatment of painful neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212-2 mesylate in the hot-plate test in mice: an isobolographic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Antiepileptic drugs in the treatment of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin induces hepatic hypoxia and increases endothelial cell proliferation in mice, a process inhibited by dietary vitamin E supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin: in the treatment of painful diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Drug safety evaluation of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Effects of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Assessment of antioxidant activity by using different in vitro methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Comparison of central versus peripheral delivery of pregabalin in neuropathic pain states

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Safety profile of treatment in diabetic peripheral neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Proteomic analysis of rosiglitazone and guggulsterone treated 3T3-L1 preadipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Assay of total antioxidant capacity: comparison of four methods as applied to human blood plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236

Efficacy and safety of pregabalin for the treatment of chronic pruritus in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1743132813Y.0000000236